Skip to content

Study · Animal study (in vivo) · mouse and rat · 2013

11 results

Hypothalamic glucagon signaling inhibits hepatic glucose production.

Mighiu PI, Yue JT, Filippi BM, Abraham MA, Chari M, Lam CK, Yang CS, Christian NR, Charron MJ, Lam TK

Nature medicine19 May 2013Cited by 103 (Europe PMC)

PMID23685839 (opens in a new tab)DOI10.1038/nm.3115 (opens in a new tab)PepBankPUB-23685839
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats under pancreatic clamp, MBH glucagon infusion activated MBH PKA.

    In plain wordsIn rats, glucagon infusion into the hypothalamus activated PKA during a pancreatic clamp.

    Peptide
    Glucagon
    Outcome
    IncreaseMBH PKA activation
    Study

    ratn: not reported in source

    rats
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    Dose not stated · mediobasal hypothalamic infusionAs given in this study (rat).

    Source sentences

    Summary
    In a pancreatic clamp setting, MBH infusion with glucagon activated MBH PKA and inhibited hepatic glucose production (HGP) in rats, as did central glucagon infusion in mice.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats under pancreatic clamp, MBH glucagon infusion inhibited hepatic glucose production.

    In plain wordsIn rats, glucagon infusion into the hypothalamus reduced liver glucose production during a pancreatic clamp.

    Peptide
    Glucagon
    Outcome
    DecreaseHepatic glucose production
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · mediobasal hypothalamic infusionAs given in this study (rat).

    Source sentences

    Summary
    In a pancreatic clamp setting, MBH infusion with glucagon activated MBH PKA and inhibited hepatic glucose production (HGP) in rats, as did central glucagon infusion in mice.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, central glucagon infusion inhibited hepatic glucose production.

    In plain wordsIn mice, central glucagon infusion reduced liver glucose production.

    Peptide
    Glucagon
    Outcome
    DecreaseHepatic glucose production
    Study

    mousen: not reported in source

    mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · central infusionAs given in this study (mouse).

    Source sentences

    Summary
    In a pancreatic clamp setting, MBH infusion with glucagon activated MBH PKA and inhibited hepatic glucose production (HGP) in rats, as did central glucagon infusion in mice.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats, a sustained rise in plasma glucagon transiently increased hepatic glucose production.

    In plain wordsIn rats, sustained glucagon elevation briefly increased liver glucose production.

    Peptide
    Glucagon
    Outcome
    IncreaseTransient hepatic glucose production response
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A sustained rise in plasma glucagon concentrations transiently increased HGP, and this transiency was abolished in rats with negated MBH glucagon action.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats without a clamp, MBH glucagon infusion improved glucose tolerance.

    In plain wordsIn rats, glucagon infusion into the hypothalamus improved glucose tolerance without a clamp.

    Peptide
    Glucagon
    Outcome
    IncreaseGlucose tolerance
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · mediobasal hypothalamic infusionAs given in this study (rat).

    Source sentences

    Summary
    In a nonclamp setting, MBH glucagon infusion improved glucose tolerance

Studies that did not test the peptide alone6

In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Glucagon.

  1. 06AnimalNot a test of Glucagon aloneAnimal study (in vivo)Mechanism

    In rats, inhibition of MBH glucagon receptor-PKA signaling negated the effect of MBH glucagon on hepatic glucose production.

    In plain wordsIn rats, blocking hypothalamic glucagon signaling prevented glucagon from reducing liver glucose production.

    Peptide
    Glucagon
    Outcome
    Direction not reportedHepatic glucose production after receptor-PKA inhibition
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Inhibition of glucagon receptor-PKA signaling in the MBH and hepatic vagotomy each negated the effect of MBH glucagon in rats, whereas the central effect of glucagon was diminished in glucagon receptor knockout mice.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  2. 07AnimalNot a test of Glucagon aloneAnimal study (in vivo)Mechanism

    In rats, hepatic vagotomy negated the effect of MBH glucagon on hepatic glucose production.

    In plain wordsIn rats, cutting hepatic vagal nerves prevented hypothalamic glucagon from reducing liver glucose production.

    Peptide
    Glucagon
    Outcome
    Direction not reportedHepatic glucose production after hepatic vagotomy
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Inhibition of glucagon receptor-PKA signaling in the MBH and hepatic vagotomy each negated the effect of MBH glucagon in rats, whereas the central effect of glucagon was diminished in glucagon receptor knockout mice.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  3. 08AnimalNot a test of Glucagon aloneAnimal study (in vivo)Mechanism

    In glucagon receptor knockout mice, the central effect of glucagon was diminished.

    In plain wordsIn mice lacking glucagon receptors, the central effect of glucagon was smaller.

    Peptide
    Glucagon
    Outcome
    DecreaseCentral glucagon effect
    Study

    mousen: not reported in source

    glucagon receptor knockout mice
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Inhibition of glucagon receptor-PKA signaling in the MBH and hepatic vagotomy each negated the effect of MBH glucagon in rats, whereas the central effect of glucagon was diminished in glucagon receptor knockout mice.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  4. 09AnimalNot a test of Glucagon aloneAnimal study (in vivo)Mechanism

    In rats with negated MBH glucagon action, the transient nature of the glucagon-induced increase in hepatic glucose production was abolished.

    In plain wordsIn rats with blocked hypothalamic glucagon action, the liver glucose response to glucagon no longer remained transient.

    Peptide
    Glucagon
    Outcome
    IncreaseDuration of hepatic glucose production response
    Study

    ratn: not reported in source

    rats with negated MBH glucagon action
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    A sustained rise in plasma glucagon concentrations transiently increased HGP, and this transiency was abolished in rats with negated MBH glucagon action.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  5. 10AnimalNot a test of Glucagon aloneAnimal study (in vivo)Mechanism

    In rats, MBH receptor-PKA inhibition enhanced the plasma glucose increase after intravenous glucagon.

    In plain wordsIn rats, blocking hypothalamic signaling increased the blood glucose response to intravenous glucagon.

    Peptide
    Glucagon
    Outcome
    IncreasePlasma glucose response after MBH signaling inhibition
    Study

    ratn: not reported in source

    rats
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    and inhibition of glucagon receptor-PKA signaling in the MBH enhanced the ability of intravenous glucagon injection to increase plasma glucose concentrations.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  6. 11AnimalNot a test of Glucagon aloneAnimal study (in vivo)Mechanism

    In rats fed a high-fat diet, disrupted MBH glucagon signaling was associated with an enhanced glucose response to glucagon.

    In plain wordsIn rats fed a high-fat diet, disrupted hypothalamic signaling was linked to a larger glucose response to glucagon.

    Peptide
    Glucagon
    Outcome
    IncreasePlasma glucose response with high-fat diet
    Study

    ratn: not reported in source

    rats fed a high-fat diet
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    We also detected a similar enhancement of glucose concentrations that was associated with a disruption in MBH glucagon signaling in rats fed a high-fat diet.
    1 context sentence
    Summary · context
    In a nonclamp setting, MBH glucagon infusion improved glucose tolerance, and inhibition of glucagon receptor-PKA signaling in the MBH enhanced the ability of intravenous glucagon injection to increase plasma glucose concentrations.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.